m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00787)
Name
TAK-603
Status
Discontinued in Phase 2
Structure
Formula
C25H26N4O6
InChI
1S/C25H26N4O6/c1-6-35-25(30)24-18(12-29-14-26-13-27-29)28-17-11-22(34-5)21(33-4)10-16(17)23(24)15-7-8-19(31-2)20(9-15)32-3/h7-11,13-14H,6,12H2,1-5H3
InChIKey
CLQRMSBSMHXMMC-UHFFFAOYSA-N
PubChem CID
153980
TTD Drug ID
D0H6PX
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Interferon-gamma (IFNG)
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Interferon-gamma (IFNG) is a therapeutic target for TAK-603. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of TAK-603 through regulating the expression of Interferon-gamma (IFNG). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Interferon-gamma (IFNG) is a therapeutic target for TAK-603. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TAK-603 through regulating the expression of Interferon-gamma (IFNG). [1], [2]
References
Ref 1 m(6) A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy. EMBO J. 2020 Oct 15;39(20):e104514. doi: 10.15252/embj.2020104514. Epub 2020 Sep 23.
Ref 2 Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-Gamma IgG1 monoclonal antibody, in patients with systemic lupus erythematosus. Pharm Res. 2015 Feb;32(2):640-53. doi: 10.1007/s11095-014-1492-2. Epub 2014 Sep 12.